Select language:

New COVID-19 vaccine registered in Russia

 / Главная / Russkiy Mir Foundation / News / New COVID-19 vaccine registered in Russia

New COVID-19 vaccine registered in Russia


27.08.2021

Photo credit: mos.ru (CC BY 4.0)

Another vaccine against coronavirus has been registered in Russia, TASS reports. The EpiVacCorona-N jab was developed by the scientists of the Vector center.

The AURORA-CoV trademark is registered in Rospatent for the name of EpiVacCorona-N. It will be used as the name for the new generation of the EpiVacCorona vaccine. The Vector Center explained that the drug differs from the previous version of EpiVacCorona. While the active ingredients remain the same, the production technology has changed.

The shelf life of the drug is six months at a temperature of 2-8 degrees Celsius. The drug is indicated for use in adults from 18 to 60 years old.

According to Grigory Ivliev, who heads Rospatent, Russian developers have a comprehensive approach to the issue of vaccine protection. They patent not only the substance itself, but also lists of ingredients, methods of application, production of individual components, as well as various forms of the vaccine.

Russkiy Mir

News by subject

Publications

Marco Maggi: ”Russian to the Bone" 20.01.2024
Italian entrepreneur Marco Maggi's book, "Russian to the Bone," is now accessible for purchase in Italy and is scheduled for release in Russia in the upcoming months. In the book, Marco recounts his personal odyssey, narrating each stage of his life as a foreigner in Russia—starting from the initial fascination to the process of cultural assimilation, venturing into business, fostering authentic friendships, and ultimately, reaching a deep sense of identifying as a Russian at his very core.